FDA Inspection 1306492 — Gul Basaran
The FDA completed an inspection of Gul Basaran on February 20, 2026 in Altunizade. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 20, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Altunizade (Turkey)
Additional Details
Clinical Investigator (CI)